Published 16 April 2018 Kalytera Therapeutics has announced the termination of its pre-clinical development programs in the treatment of bone disease to focus its resources on graft versus host disease (GVHD) and pain programs. The company has determined that additional investments of time and resources in these programs are not appropriate given the other opportunities […]

by

SAN FRANCISCO TEL AVIV, ISRAEL–(Business Wire)–Kalytera Therapeutics, Inc. (TSX VENTURE: KALY and OTCQB: KALTF) (the “Company” or “Kalytera“) today announced the termination of its pre-clinical development programs in the treatment of bone disease. The Company has determined that additional investments of time and resources in these programs are not appropriate given the other opportunities in […]

by

A demonstration outside the State Capitol in support of medical marijuana. By the time Ann Marie Owen turned to marijuana to treat her pain, she was struggling to walk and talk. She also hallucinated. For four years, her doctor prescribed the 61-year-old a wide range of opioids for her transverse myelitis, a debilitating disease that […]

by

(RTTNews) – The week that went by started with a couple of big-ticket deals being inked. Swiss pharmaceutical giant Novartis (NVS), on April 9th, agreed to acquire clinical-stage gene therapy company AveXis Inc. (AVXS) for $218 per share or a total approximate value of $8.7 billion. Alexion Pharmaceuticals (ALXN), on April 11th, announced that is […]

by

When it comes to fighting drug and alcohol addictions, marijuana may be a powerful secret weapon. According to a study recently published in “Neuropsychopharmacology,” cannabidiol, or CBD — a substance found in cannabis — could potentially reduce the risk of relapse in patients recovering from drug or alcohol addiction, Fortune reports. The preclinical study, performed […]

by

Devon, PA (GLOBE NEWSWIRE) – Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty neuropsychiatric pharmaceutical company dedicated to developing and commercializing innovative pharmaceutically-produced transdermal cannabinoid treatments for rare and near-rare neurological and psychiatric disorders with high unmet medical needs, today announced that it has initiated the Phase 2 BELIEVE 1 (Open Label Study to Assess the […]

by

Kalytera Therapeutics will terminate its pre-clinical development programs in the treatment of bone disease. The company has determined that additional investments of time and resources in these programs are not appropriate given the other opportunities in its product development pipeline. The terminated programs were evaluating three synthetic endocannabinoid compounds, KAL436, KAL439 and KAL671, in bone fracture […]

by

LONDON, April 12, 2018 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (GWPH) “GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, along with its U.S. subsidiary Greenwich Biosciences, today announced that the Company will present data from the pivotal Phase 3 trials […]

by

LONDON, April 12, 2018 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq:GWPH) “GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, along with its U.S. subsidiary Greenwich Biosciences, today announced that the Company will present data from the pivotal Phase 3 trials […]

by

LONDON, April 12, 2018 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (GWPH) “GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, along with its U.S. subsidiary Greenwich Biosciences, today announced that the Company will present data from the pivotal Phase 3 trials […]

by

DEVON, Pa., April 10, 2018 (GLOBE NEWSWIRE) — Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty neuropsychiatric pharmaceutical company dedicated to developing and commercializing innovative pharmaceutically-produced transdermal cannabinoid treatments for rare and near-rare neurological and psychiatric disorders with high unmet medical needs, today announced that it has initiated the Phase 2 BELIEVE 1 (Open Label Study […]

by